Cytek's 6% Q2 Growth Came With a Profit Tax-Why the Stock Still Has Stakes at $4

Demand is back, but profitability is the new test

Cytek posted second-quarter revenue of $48.1 million, up 6% year over year, but the wider loss left little room for error. Shares ended around $4.04 after earnings, reflecting a market that appears willing to support a recovery story only if it starts to show a path to profit. For now, the core debate is simple: demand looks healthier, but investors want proof that more cash remains in the business after it is earned.

U.S. and China growth support the recurring-revenue case

The demand story does not look cosmetic. U.S. revenue rose 18% and China posted strong double-digit growth, while service revenue climbed 10%. Combined reagents and service revenue also increased, which suggests customers are continuing to buy into Cytek's broader ecosystem rather than making only one-off instrument purchases. That is the setup bulls find most appealing because it can support a steadier revenue base over time.

The margin problem still limits the bullish case

The quarter's main drag was profitability. Gross margin was 59% including a one-time $2.8 million tariff refund, or 53% excluding it. Operating expenses rose 15%, and Cytek reported a $11.4 million loss from operations and adjusted EBITDA of negative $1.5 million. That is exactly where skeptics focus when spending rises faster than leverage.

Guidance keeps the focus on execution, not just growth

Cytek raised the low end of its full-year 2026 revenue guidance to $207 million to $212 million. That matters because the stock no longer needs proof that demand has returned; it needs evidence that margin discipline and expense control can improve alongside growth. If management can hold that guidance while operating performance stabilizes, the next few quarters become more credible. If not, the market is unlikely to reward the recovery narrative on growth alone.